During the past decade, S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 6 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 17 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 15 trials sponsored, "Hoffmann-La Roche" with 6 trials sponsored, "Fondazione per la Ricerca Ospedale Maggiore" with 4 trials sponsored and "Gruppo Italiano Trapianto di Midollo Osseo" with 4 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo" #1 collaborator was "Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "AOP Orphan Pharmaceuticals AG" with 1 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "Biogen" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo" are "Chronic Myeloid Leukemia" (5 trials), "Acute Promyelocytic Leukemia" (3 trials), "Chronic Lymphocytic Leukemia" (3 trials), "Follicular Lymphoma" (3 trials) and "Myelofibrosis" (3 trials). Many other conditions were trialed in "S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo" in a lesser frequency.

Most popular intervention types in "S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo" are "Drug" (35 trials), "Other" (8 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (6 trials), "Bendamustine" (4 trials), "Cyclophosphamide" (3 trials), "Doxorubicin" (2 trials) and "Ibrutinib" (2 trials). Other intervention names were less common.

The vast majority of trials in "S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo" are 46 trials for "All" genders.

Currently, there are NaN active trials in "S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo". undefined are not yet recruiting, 3 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo, 0 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".